1-Arroyo V et al,2013:Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in ascites: pathophysiological basis of therapy and current management. J Hepatol 2013;38(Suppl 1):S69–89.
2-Arroyo V et al,2009:Arroyo V, Gine`s P, Gerbes A, et al. Definition and Arroyo V, Gines P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 2009;23:164–76.
3-Bellot p et al,2011: Van Putten VJ, Schrier RW (2011) Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 307: 1552-1557.
4-Estrailian E et al,2010:Estrailian E, Pantangco ER, Kyulo NL, et al. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.Dig Dis Sci 2010;52:742–8.al
5-Gines A et al,2010:Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 2010;17:220–6.
6-Guevara M et al,2014:Guevara M, Fernandez-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 2014;40:646–51.
7-Hadengue A et al,2010:Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 2010;29:565–70.
8-NakaeH et al,2007:NakaeH, IgarashiT,TajimiK, et al.Acase reportof hepatorenal syndrome treatedwith plasma diafiltration (selective plasma f Planas R et al,2009:Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2009;4:1385–94.
9-Portal A et al,2010: Portal A, Bruce M, Austin M, et al. Renal dysfunction following liver transplantation: a comparison of novel renal biomarkers in the post transplant period. Hepatology 2010; 46(Suppl 1):501A. iltration with dialysis). Ther Apher Dial 2007;11(5):391–5.
10-Salerno F et al,2007:Salerno F, Camma C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133: 825.
11-Sanyal A et al,2013:Sanyal A, Boyer T, Teuber P, et al. Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 HRS enrolled in a randomized double blind placebo controlled trial. Hepatology 2013;46(Suppl 1):564A.
12-Hoyert DL et al,2012:Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012; 61: 1–52.
13-Laleman W et al,2016: Laleman W, Wilmer A, Evenepoel P, Elst IV, Seegers M, Zaman Z, et al. Crit Care 2016;10:R108.
14-Lee HP et al,2014:Lee HP, Chew L, Chow KY, Khaing TT, Loy EY, Ho W: Singapore Cancer Registry Interim Annual Registry Report: Trends in Cancer Incidence in Singapore 2009–2014. Health Promot Board Singap 2014
15-Nazar A et al,2010:Nazar A, Pereira GH, Guevara M, Martin-Llahí M, Pepin MN, et al. Predictors of response to therapy to terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010;51:219–226.
16-Pe´ron JM et al,2015:Pe´ron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2015;100:2702–7.
17-Portal A et al,2011: Portal A, Bruce M, Austin M, et al. Renal dysfunction following liver transplantation: a comparison of novel renal biomarkers in the post transplant period. Hepatology 2011; 46(Suppl 1):501A.